Premium
Surfactant replacement therapy in neonates with respiratory failure due to bacterial sepsis
Author(s) -
Fetter WPF,
Baerts W,
Bos AP,
Lingen RA van
Publication year - 1995
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.1995.tb13476.x
Subject(s) - medicine , dose , sepsis , respiratory failure , surfactant therapy , respiratory system , gestational age , pulmonary surfactant , anesthesia , oxygen therapy , respiratory disease , airway , surgery , pregnancy , lung , physics , biology , genetics , thermodynamics
We describe four newborns (gestational ages 29‐37 weeks; birthweights 1380‐3040 grams) who were mechanically ventilated for respiratory insufficiency because of bacterial sepsis. A beneficial effect of bovine surfactant (Alvofact, dosages 50 or lOOmg/kg) was found, as shown by decreases in mean airway pressures and oxygen demands. No side effects were seen after instillation.